Biogenics Inc.

Daejeon, South Korea

Biogenics Inc.

Daejeon, South Korea
SEARCH FILTERS
Time filter
Source Type

SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the signing of an exclusive license and distribution agreement with Densmore Pharmaceutical International (“Densmore”), a company based in Monaco for the commercialization of Zestra® in France and Belgium. “We are pleased to expand the commercialization market for Zestra® in the European Union to France and Belgium,” said Innovus Pharma CEO, Dr. Bassam Damaj. “Densmore is our 15th distribution partner for our products outside the United States and is very important for us to compete in one of the largest markets in Europe” said Innovus CEO Dr. Bassam Damaj. “This partnership is one more step towards achieving our 2017 corporate goals for revenue and profitability from our international distributors,” continued Dr. Damaj. “We are excited to commercialize Zestra for the French and the Belgium market as it will fulfill a large unmet medical need. Zestra is a very well-studied project with strong placebo controlled clinical trials and we believe it will provide a strong natural solution for women,” said Dr. Philippe Caron CEO of Densmore, and an authority on women’s health products in the French market. Zestra® is currently exclusively partnered with Orimed Pharma, the OTC subsidiary of Jamp Pharma in Canada, DanaLife ApS in select European markets, Sothema Laboratories for the Middle East and North Africa, Elis Pharmaceuticals in Turkey and certain select markets, Oz Biogenics for Myanmar and Vietnam, BioTask in Malaysia and J&H Co. LTD in South Korea, and non-exclusively to PT Resources in Hong Kong and certain select Asian markets. Zestra® is approved in Canada, the 28 countries of the European Union, India, Hong Kong, the United Arab Emirates (“UAE”), United Kingdom and Morocco. Innovus currently generates revenues from the following markets for Zestra®: Canada, Morocco, certain European countries and Hong Kong in addition to the United States as its biggest market. Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. To the Company’s knowledge, Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada. To date, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger. Approximately 43% of women in the United States age 18 to 59, or ~50 million, experience some form of Female Sexual Dysfunction (“FSD”) according to a published study. (Laumann, E.O. et al. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999. vol. 281, No. 6.537-542) and (http://www.indexmundi.com/south_korea/demographics_profile.html). The FSD market in the United States is estimated to be more than $1 billion per year. For more information on Zestra® visit www.zestra.com. Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC. For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.fluticare.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.prostagorx.com Densmore is based in Monaco and has been in operation since 1946. Its research and development center has about 70 years of expertise in vitamin therapy and micro-nutrition formulas. Since the early 2000's, Densmore has acquired new skills in drugs, medical devices and cosmetics. It received two innovations and research awards for the entire range. In addition to its presence in France, Densmore is exported to many countries in Europe and north Africa. Densmore’s aim is to make available to all, the medical professions and patients, innovative products that combine safety, security and easy to use to meet the health needs and well-being in everyday life. See www.densmore.mc. Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to successfully commercialize Zestra® and other products in France, Belgium and in other countries in the European Union, the U.S. and internationally and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.


SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the signing of an exclusive license and distribution agreement with Luminarie Pty Ltd (“Luminarie”), a company based in Australia for the commercialization of Zestra® and Zestra Glide® in Australia, New Zealand and the Philippines. “Part of our plan to increase revenues from our international distributors is to expand into the Asia-Pacific region,” said Innovus Pharma CEO Dr. Bassam Damaj. “We are very happy to be teaming-up with Luminarie in Australia, New Zealand and the Philippines to market our Zestra® and Zestra Glide® products. Luminaire is now our 16th distribution partner for our products outside the United States and we look forward to expanding our sales into these important countries with them,” continued Dr. Damaj. “We are delighted to be working with Innovus Pharma on the commercialization of their Zestra® and Zestra Glide® products into Australia, New Zealand and the Philippines,” said Hemant Gulhane, CEO of Luminarie. “We love the fact that these products represent a well-known brand with extensive clinical trials. We believe each product will be well received in these countries and will meet a large unmet patient need.” Zestra® is currently exclusively partnered with Orimed Pharma, the OTC subsidiary of Jamp Pharma in Canada, Densmore Pharmaceutical International in France and Belgium, DanaLife ApS in select European markets, Sothema Laboratories for the Middle East and North Africa, Elis Pharmaceuticals in Turkey and certain select markets, Oz Biogenics for Myanmar and Vietnam, BioTask in Malaysia and J&H Co. LTD in South Korea, and non-exclusively to PT Resources in Hong Kong and certain select Asian markets. Zestra® is approved in Canada, the 28 countries of the European Union, India, Hong Kong, the United Arab Emirates (“UAE”), United Kingdom and Morocco. Innovus currently generates revenues from the following markets for Zestra®: Canada, Morocco, South Korea, certain European countries and Hong Kong in addition to the United States as its biggest market. Zestra® is a patented blend of natural oils clinically proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. To the Company’s knowledge, Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada. To date, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger. Approximately 43% of women in the United States age 18 to 59, or ~50 million, experience some form of Female Sexual Dysfunction (“FSD”) according to a published study. (Laumann, E.O. et al. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999. vol. 281, No. 6.537-542) and (http://www.indexmundi.com/south_korea/demographics_profile.html). The FSD market in the United States is estimated to be more than $1 billion per year. For more information on Zestra®, please visit www.zestra.com. Zestra Glide® is currently exclusively partnered with Orimed Pharma in Canada, Sothema Labs in the Middle East and North Africa, Elis Pharma in Turkey and certain select markets, Oz Biogenics in Myanmar and Vietnam, and KLabs in India. Zestra Glide® is currently approved in 32 countries and marketed and sold in three countries, including the United States, Canada and Morocco. For more information on Zestra Glide®, please visit www.zestra.com/glide. Zestra Glide® is the only water-based clinically tested lubricant with high viscosity. Increased viscosity usually translates into longer effects. The lubricant market is estimated to be around $200 million in the U.S. (Symphony IRI Group Study, 2012). Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC. For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.fluticare.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.prostagorx.com. Luminarie is an innovative healthcare company, operating in Australia, New Zealand, the Philippines, China and Canada, bringing to market new unique products within the consumer healthcare and pharmaceutical space. With an experienced team of pharmaceutical industry professionals, Luminaire is building a portfolio of brands that consumers will come to recognize and love. Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to successfully commercialize Zestra®, Zestra Glide® and other products in Australia, New Zealand and the Philippines and in other countries in the European Union, the U.S. and internationally and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.


C. Norman Shealy, M.D., Ph.D., D.Sc. Honored as Biography of the Month for April 2017 by Strathmore's Who's Who Worldwide Publication Fair Grove, MO, May 13, 2017 --( About C. Norman Shealy, M.D., Ph.D., D.Sc. Dr. Shealy is the Founder and CEO of the International Institute of Holistic Medicine which is a holistic practice providing patient care targeting pain management, depression and holistic medicine in Springfield, Missouri. He is one of the world’s leading experts in pain management and the first physician to specialize in the resolution of chronic pain. A pioneer in developing safe and effective treatments such as Biogenics, in 1971 he founded the first comprehensive pain and stress management facility in the country, the Shealy Institute, respected world-wide for its innovative and successful rehabilitation approaches in over 30,000 patients. He retired from practicing after 60 years of medical and holistic experience. In the last year he has reopened his world renowned holistic clinic as the International Institute of Holistic Medicine, with Dr. Sergey Sorin joining him. He has acted as a consultant to leaders in every specialty, including the personal physicians of Presidents Kennedy and Eisenhower. He has received numerous awards in his field. Dr. Shealy holds 12 patents for his work by creating safe alternatives to drugs and surgery. Over the years, Dr. Shealy’s intense pain and stress management research has resulted in numerous pioneering treatments. At the forefront of alternative medicine and alternative healthcare, he founded the American Holistic Medical Association, which led to almost 30 years of research into an emphasis on anti-aging. He discovered five energetic acupuncture circuits, which help balance people’s elemental energies. Dr. Shealy calls them Ring of Fire, Ring of Air, Ring of Water, Ring of Earth, and Ring of Crystal. The Ring of Fire began when Norm first started research on how to increase DHEA, the most abundant circulating steroid hormone in humans that is produced in the adrenal glands, the gonads, and the brain. Using only a simple roll-on to stimulate 12 specific points on the body, it will affect the functions of kidney, conception vessels, bladder, heart, large intestine, and governing vessel leading to an average increase in DHEA of 60%. Applying this approach to different diseases, Norm found that, depending on the diseases, 70 to 80% of patients improved dramatically. The Ring of Air began when Dr. Shealy sensed that activating the air circuit would assist with hearing, tinnitus, mental creativity or intuition, mystical insight, integration, and non-separatism. Using the same stimulation on different points he discovered a significant increase in Neurotensin, a natural neuroleptic and anti-nocioceptic. The Ring of Water was developed because a human body consists of over 75% water, and water energy is essential for emotional balance, edema, and contacting the Christological heart. When stimulated daily, with the Ring of Fire, it also assists in weight loss. It is most useful clinically in treating congestive heart failure and edema. Stimulating the Ring of Earth raises calcitonin, the thyroid produced hormone that helps maintain bone integrity. Calcitonin also is the strongest pain reliever the body produces. The human body is piezoelectric, similar to the quality in quartz crystal. The Ring of Crystal is for overall balance of the energetic system and to assist in regeneration. Stimulation of the Ring of Crystal leads to 85% reduction in free radicals within three to five days. Dr. Shealy is affiliated with the Greene County Medical Society, the A.M.A. and the A.C.I.M. Dr. Shealy is the President of Holos Energy Medicine Education and is a Professor Emeritus of Energy Medicine at Holos University Graduate Seminary. He is Tiwehkt of the Native American Church of Nemenhah. Currently, Dr. Shealy is researching and serving on various boards and affiliations. He is the Editor of the “Journal of Comprehensive Integrative Medicine.” He has authored and co-authored over 325 publications and articles, has a 90 minute DVD called “Medical Renaissance: The Secret Code” which demonstrates the success of a comprehensive, holistic approach to almost all illnesses and has over 10 patents. Dr. Shealy regularly hosts and appears on talk radio. His seminars and workshops are given worldwide, and are attended by physicians and laypersons alike. Born on December 4, 1932, Dr, Shealy obtained a B.S. in 1952 and an M.D. in 1956, both from Duke University. He obtained a Ph.D. from Saybrook Institute in San Francisco in 1977 and a D.Sc. from Ryodoraku Research Institute of North America, Inc. in Kansas City, Missouri in 1979. He has held teaching positions at Western Reserve Medical School, the University of Wisconsin, and the University of Minnesota Medical School’s Forest Institute of Professional Psychology. Dr. Shealy holds specialty board certifications from the American Board of Neurological Surgery, Biofeedback Certification Institute of America, and American Boards of Medical Psychotherapists, Pain Management, Somnology and Sexology. In his spare time Dr. Shealy enjoys gardening. Dr. Shealy states, “The only purpose in life is to help others.” For further information, contact About Strathmore’s Who’s Who Worldwide Strathmore’s Who’s Who Worldwide highlights the professional lives of individuals from every significant field or industry including business, medicine, law, education, art, government and entertainment. Strathmore’s Who’s Who Worldwide is both an online and hard cover publication where we provide our members’ current and pertinent business information. It is also a biographical information source for thousands of researchers, journalists, librarians and executive search firms throughout the world. Our goal is to ensure that our members receive all of the networking, exposure and recognition capabilities to potentially increase their business. Fair Grove, MO, May 13, 2017 --( PR.com )-- C. Norman Shealy, M.D., Ph.D., D.Sc. of Fair Grove, Missouri has been honored as our Biography of the Month for April 2017 by Strathmore’s Who’s Who Worldwide Edition for his outstanding achievements and high level of success for over 60 years in the field of holistic healthcare.About C. Norman Shealy, M.D., Ph.D., D.Sc.Dr. Shealy is the Founder and CEO of the International Institute of Holistic Medicine which is a holistic practice providing patient care targeting pain management, depression and holistic medicine in Springfield, Missouri. He is one of the world’s leading experts in pain management and the first physician to specialize in the resolution of chronic pain. A pioneer in developing safe and effective treatments such as Biogenics, in 1971 he founded the first comprehensive pain and stress management facility in the country, the Shealy Institute, respected world-wide for its innovative and successful rehabilitation approaches in over 30,000 patients. He retired from practicing after 60 years of medical and holistic experience. In the last year he has reopened his world renowned holistic clinic as the International Institute of Holistic Medicine, with Dr. Sergey Sorin joining him. He has acted as a consultant to leaders in every specialty, including the personal physicians of Presidents Kennedy and Eisenhower. He has received numerous awards in his field. Dr. Shealy holds 12 patents for his work by creating safe alternatives to drugs and surgery.Over the years, Dr. Shealy’s intense pain and stress management research has resulted in numerous pioneering treatments. At the forefront of alternative medicine and alternative healthcare, he founded the American Holistic Medical Association, which led to almost 30 years of research into an emphasis on anti-aging. He discovered five energetic acupuncture circuits, which help balance people’s elemental energies. Dr. Shealy calls them Ring of Fire, Ring of Air, Ring of Water, Ring of Earth, and Ring of Crystal.The Ring of Fire began when Norm first started research on how to increase DHEA, the most abundant circulating steroid hormone in humans that is produced in the adrenal glands, the gonads, and the brain. Using only a simple roll-on to stimulate 12 specific points on the body, it will affect the functions of kidney, conception vessels, bladder, heart, large intestine, and governing vessel leading to an average increase in DHEA of 60%. Applying this approach to different diseases, Norm found that, depending on the diseases, 70 to 80% of patients improved dramatically.The Ring of Air began when Dr. Shealy sensed that activating the air circuit would assist with hearing, tinnitus, mental creativity or intuition, mystical insight, integration, and non-separatism. Using the same stimulation on different points he discovered a significant increase in Neurotensin, a natural neuroleptic and anti-nocioceptic.The Ring of Water was developed because a human body consists of over 75% water, and water energy is essential for emotional balance, edema, and contacting the Christological heart. When stimulated daily, with the Ring of Fire, it also assists in weight loss. It is most useful clinically in treating congestive heart failure and edema.Stimulating the Ring of Earth raises calcitonin, the thyroid produced hormone that helps maintain bone integrity. Calcitonin also is the strongest pain reliever the body produces.The human body is piezoelectric, similar to the quality in quartz crystal. The Ring of Crystal is for overall balance of the energetic system and to assist in regeneration. Stimulation of the Ring of Crystal leads to 85% reduction in free radicals within three to five days.Dr. Shealy is affiliated with the Greene County Medical Society, the A.M.A. and the A.C.I.M. Dr. Shealy is the President of Holos Energy Medicine Education and is a Professor Emeritus of Energy Medicine at Holos University Graduate Seminary. He is Tiwehkt of the Native American Church of Nemenhah.Currently, Dr. Shealy is researching and serving on various boards and affiliations. He is the Editor of the “Journal of Comprehensive Integrative Medicine.” He has authored and co-authored over 325 publications and articles, has a 90 minute DVD called “Medical Renaissance: The Secret Code” which demonstrates the success of a comprehensive, holistic approach to almost all illnesses and has over 10 patents. Dr. Shealy regularly hosts and appears on talk radio. His seminars and workshops are given worldwide, and are attended by physicians and laypersons alike.Born on December 4, 1932, Dr, Shealy obtained a B.S. in 1952 and an M.D. in 1956, both from Duke University. He obtained a Ph.D. from Saybrook Institute in San Francisco in 1977 and a D.Sc. from Ryodoraku Research Institute of North America, Inc. in Kansas City, Missouri in 1979. He has held teaching positions at Western Reserve Medical School, the University of Wisconsin, and the University of Minnesota Medical School’s Forest Institute of Professional Psychology. Dr. Shealy holds specialty board certifications from the American Board of Neurological Surgery, Biofeedback Certification Institute of America, and American Boards of Medical Psychotherapists, Pain Management, Somnology and Sexology. In his spare time Dr. Shealy enjoys gardening.Dr. Shealy states, “The only purpose in life is to help others.”For further information, contact www.normshealy.com About Strathmore’s Who’s Who WorldwideStrathmore’s Who’s Who Worldwide highlights the professional lives of individuals from every significant field or industry including business, medicine, law, education, art, government and entertainment. Strathmore’s Who’s Who Worldwide is both an online and hard cover publication where we provide our members’ current and pertinent business information. It is also a biographical information source for thousands of researchers, journalists, librarians and executive search firms throughout the world. Our goal is to ensure that our members receive all of the networking, exposure and recognition capabilities to potentially increase their business. Click here to view the list of recent Press Releases from Strathmore Worldwide


Cho H.-J.,Seoul National University | Yoon I.-S.,Seoul National University | Yoon H.Y.,Korea Institute of Science and Technology | Koo H.,Korea Institute of Science and Technology | And 7 more authors.
Biomaterials | Year: 2012

Polyethylene glycol (PEG)-conjugated hyaluronic acid-ceramide (HACE) was synthesized for the preparation of doxorubicin (DOX)-loaded HACE-PEG-based nanoparticles, 160 nm in mean diameter with a negative surface charge. Greater uptake of DOX from these HACE-PEG-based nanoparticles was observed in the CD44 receptor highly expressed SCC7 cell line, compared to results from the CD44-negative cell line, NIH3T3. A strong fluorescent signal was detected in the tumor region upon intravenous injection of cyanine 5.5-labeled nanoparticles into the SCC7 tumor xenograft mice; the extended circulation time of the HACE-PEG-based nanoparticle was also observed. Pharmacokinetic study in rats showed a 73.0% reduction of the in vivo clearance of DOX compared to the control group. The antitumor efficacy of the DOX-loaded HACE-PEG-based nanoparticles was also verified in a tumor xenograft mouse model. DOX was efficiently delivered to the tumor site by active targeting via HA and CD44 receptor interaction and by passive targeting due to its small mean diameter (<200 nm). Moreover, PEGylation resulted in prolonged nanoparticle circulation and reduced DOX clearance rate in an in vivo model. These results therefore indicate that PEGylated HACE nanoparticles represent a promising anticancer drug delivery system for cancer diagnosis and therapy. © 2011 Elsevier Ltd.


Provided is a three-layered capsule using a hollow silica capsule containing a stabilizer, a hydrogel polymer consisting of a polymer blend, and an appropriately hydrophobic polymer. The principal components of the present invention include a single-layered capsule formed from water-insoluble substances, a stabilizer, and a hollow silica; a double-layered capsule having a hydrogel polymer blend surrounding the outside of the single-layered capsule; and a three-layered capsule having a hydrophobic polymer surrounding the outside of the double-layered capsule.


The present invention relates to a three-layered capsule using a hollow silica capsule containing a stabilizer, a hydrogel polymer consisting of a polymer blend, and an appropriately hydrophobic polymer. The principal components of the present invention include a single-layered capsule formed from water-insoluble substances, a stabilizer, and a hollow silica; a double-layered capsule having a hydrogel polymer blend surrounding the outside of the single-layered capsule; and a three-layered capsule having a hydrophobic polymer surrounding the outside of the double-layered capsule.


Disclosed herein are a color capsule composition, which contains a polymer and a plasticizer swelling the polymer so as to allow the capsule particles to easily break and in which the capsule particles have a porous structure that boosts the effects thereof, and a method for preparing the color capsule composition. The preparation method comprises: uniformly mixing a color pigment, a plasticizer and a polymer in a first solvent to produce a first mixture solution; spray-drying the first mixture solution to produce core particles in which the color pigment is covered by the polymer; uniformly mixing the obtained core particles, a functional pigment and a second solvent to produce a second mixture solution; and spray-drying the second mixture solution to produce in which a coating layer of the functional pigment is formed on the outer surface of the polymer.


The present invention relates to a capsule composition containing UV-blocking inorganic nanoparticles, and a preparation method thereof, in which the UV-blocking inorganic nanoparticles are embedded in hydrophilic polymer capsules using a water-soluble dispersing agent, so that when the composition is applied to the skin, the polymer forms a thin hydrogel film that keeps the inorganic nanoparticles contained in the capsules to prevent the inorganic nanoparticles from penetrating the skin. The method comprises: uniformly mixing UV-blocking inorganic nanoparticles with a water-soluble dispersing agent in water to prepare a dispersion of the inorganic nanoparticles coated with the dispersing agent; adding, to the dispersion, either a hydrophilic polymer capable of forming a hydrogel, or a solution of the hydrophilic polymer in distilled water, to prepare a mixture; and spray-drying the mixture, thereby producing capsule particles containing the dispersing agent-coated UV-blocking inorganic nanoparticles covered by a film formed of the hydrophilic polymer.


Provided is a method of solubilizing a poorly soluble/insoluble active material through formation of an oligomer composite, in which a structure having a hydrophobic cavity structure is formed by using oligomers derived from two types of hydrophilic natural polymers and a poorly soluble/insoluble component is encapsulated in the cavity structure, and thus, self-aggregation of the poorly soluble/insoluble material is prevented and simultaneously, thermodynamic stability increases to effectively solubilize the poorly soluble/insoluble material. According to the constitution of the present invention, the method may include a first operation of preparing an oligomer composite having a cavity structure formed therein by mixing and dissolving oligomers derived from two types of hydrophilic natural polymers in water, and a second operation of adding a poorly soluble/insoluble material to the oligomer composite to encapsulate the poorly soluble/insoluble material in the hydrophobic cavity structure of the oligomer composite.


A capsule composition containing UV-blocking inorganic nanoparticles, and a preparation method thereof, in which the UV-blocking inorganic nanoparticles are embedded in hydrophilic polymer capsules using a water-soluble dispersing agent, so that when the composition is applied to the skin, the polymer forms a thin hydrogel film that keeps the inorganic nanoparticles contained in the capsules to prevent the inorganic nanoparticles from penetrating the skin. The method comprises: uniformly mixing UV-blocking inorganic nanoparticles with a water-soluble dispersing agent in water to prepare a dispersion of the inorganic nanoparticles coated with the dispersing agent; adding, to the dispersion, either a hydrophilic polymer capable of forming a hydrogel, or a solution of the hydrophilic polymer in distilled water, to prepare a mixture; and spray-drying the mixture, thereby producing capsule particles containing the dispersing agent-coated UV-blocking inorganic nanoparticles covered by a film formed of the hydrophilic polymer.

Loading Biogenics Inc. collaborators
Loading Biogenics Inc. collaborators